胰岛素蛋白质工程;[B9Glu,B10Asp]人胰岛素

用缺口双链ＤＮＡ的定向突变方法分别将胰岛素Ｂ链第９和第１０位的Ｓｅｒ和Ｈｉｓ改变为Ｇｌｕ和Ａｓｐ,获得「Ｂ９Ｇｌｕ,Ｂ１０Ａｓｐ」人胰岛素。其受体结合能力为猪胰岛素的３４．４％,而体内活力与猪胰岛素基本相同     

饥饿状态大鼠胰腺胰高血糖素和胰岛素变化的定量分析

用免疫组织化学方法结合图象分析技术对饥饿状态大鼠胰岛Ａ、Ｂ细胞中胰高血糖素（Ｇｌｕｃａｇｏｎ,Ｇｌｕ）和胰岛素（Ｉｎｓｕｌｉｎ,Ｉｎｓ）的免疫反应强度进行定量分析。结果表明：与正常对照相比,饥饿大鼠胰岛Ａ细胞中的Ｇｌｕ含量明显下降,Ｂ细胞中Ｉｎｓ含量明显升高。提示饥饿可导致Ｇｌｕ释放增加,Ｉｎｓ释放减少。与饥饿５天大鼠组相比较,饥饿５天后静脉注射葡萄糖组９０ｍｉｎ后胰岛内Ｇｌｕ含量明显升高,Ｉｎｓ含量无显著变化。提示：静脉注射葡萄糖可快速作用于胰岛Ａ细胞,减少Ｇｌｕ释放,但其对Ｂ细胞作用缓慢。从而为进一步阐明葡萄糖对胰岛Ａ、Ｂ细胞的不同作用机制提供形态学依据。     

饥饿状态大鼠胰腺高血糖素和胰岛素变化的定量分析

用免疫组织化学方法结合图象分析技术对饥饿状态大鼠胰岛Ａ、Ｂ细胞中胰因糖素和胰岛素的免疫反应强度进行定量分析。结果表明：与正常对照相比,饥饿大鼠胰岛细胞中的Ｇｌｕ含量明显下降,Ｂ细胞中Ｉｎｓ含量明显升高。提示饥饿可导致Ｇｌｕ释放增加,Ｉｎｓ和减少。与饥饿５天大鼠线要比较,饥饿５天后静脉注射葡萄糖组９０ｍｉｎ后胰岛内Ｇｌｕ含量明显升高,Ｉｎｓ含量无显著变化。提示：静脉注射葡萄糖要快速作用下胰岛Ａ细胞,     

双链杂交分子“胰岛素－类胰岛素生长因子－I

以去Ｂ链Ｃ端八肽胰岛素（ＤＯＩ）和化学合成的ＩＧＦ－Ｉ的２２～２９（８肽）及２２－３２（１１肽）为底物,用酶促半合成方法制备了杂交分子“胰岛素－类胰岛素生长因子－Ｉ,Ｉｎｓ／ＩＧＦ－Ｉ（８）和Ｉｎｓ／ＩＧＦ－Ｉ（１１）。研究了它们的胰岛素生物活性,结果表明,猪胰岛素Ｂ链Ｃ端Ｂ２７的Ｔｈｒ被Ａｓｎ取代,Ｂ３０的Ａｌａ被Ｔｈｒ取代同时Ｂ２５～Ｂ２６及Ｂ２８－Ｂ２ｋ９氨基酸顺序颠倒以及在Ｂ链Ｃ末端延长３肽（Ｇｌｙ－Ｔｙｒ－Ｇｌｙ）都不影响胰岛素的生物活力。     

3个六肽的胰岛素受体结合和体内生物活性

为了研究胰岛素受体结合部位的结构和功能,设计并用固相方法合成了３个六肽．在浓度大于１×１０３ｎｍｏｌ／Ｌ时,ｃｙｃｌｏ（Ｐｈｅ－Ｐｈｅ－Ｖａｌ－Ｌｅｕ－Ｔｙｒ－Ｇｌｙ）具有明显的胰岛素受体结合活力;Ｈ－Ｐｈｅ－Ｐｈｅ－Ｖａｌ－Ｌｅｕ－Ｔｙｒ－Ｇｌｙ－ＯＨ的这一活力则不明显;而Ｈ－Ｇｌｙ－Ｇｌｕ－Ａｒｇ－Ｇｌｙ－Ｐｈｅ－Ｐｈｅ－ＯＨ则增强胰岛素和其受体的亲和性．然而,它们都没有体内生物活性．这表明：环六肽部分模拟了胰岛素受体结合部位的空间构象;胰岛素受体结合部位的疏水性和其中的Ｂ２３Ｇｌｙ－Ｂ２４Ｐｈｅ－Ｂ２５Ｐｈｅ对胰岛素和其受体的结合起重要作用．     

B8Gly在胰岛素结构模体中的可能作用

在胰岛素结构模体ｎ１－Ｃｙｓ－Ｇｌｙ－Ｘ１０－Ｃｙｓ－ｎ２－Ｃｙｓ－Ｃｙｓ－Ｘ３－Ｃｙｓ－Ｘ８－Ｃｙｓ－ｎ３中,有７个绝对保守的氨基酸残基,只有位于Ｂ８位的是Ｇｌｙ。通过定点突变将其改变为Ａｌａ,得到「Ｂ８Ａｌａ」人胰岛素,其受体结合能力和体内生物活力分别为天然猪胰岛素的２．５％和１０％。「Ｂ８Ａｌａ」人胰岛素和重组人胰岛素的远紫外圆二色谱比较表明,「Ｂ８Ａｌａ」人胰岛素的α－螺旋的相对含量有一家     

双链杂交分子“胰岛素—类胰岛素生长因子—I”

以去Ｂ链Ｃ端八肽胰岛素和化学合成的ＩＧＦ－Ｉ的２２－２９及２２－３２为底物,用酶促半合成方法制备了杂交分子“胰岛素－类胰岛素茵子－Ｉ”,Ｉｎｓ／ＩＧＦ－Ｉ和Ｉｎｓ－ＩＧＦ－Ｉ。研究了它们的胰岛中生物活性。结果表明,猪胰岛素Ｂ链Ｃ端Ｂ２７的Ｔｈｒ被Ａｓｎ取代,Ｂ３０的Ａｌａ被Ａｌａ被Ｔｈｒ取代同时Ｂ２５－Ｂ２６及Ｂ２８－Ｂ２９氨基酸顺序颠紧及在Ｂ链Ｃ末端延长３肽都不影响胰岛素的生物活力。     

用富集文库克隆人胰岛素基因组基因

通过构建可富集人胰岛素基因的λ噬菌体文库,克隆了人胰岛素基因组基因．首先从中国人血液白细胞中提取到人基因组ＤＮＡ,用ＥｃｏＲⅠ和ＢｇｌⅡ对基因组ＤＮＡ进行全酶切,经０．４％琼脂糖凝胶电泳,特异回收９．５ｋｂ左右的ＤＮＡ片段．将该片段与λＥＭＢＬ３／ＢａｍＨⅠ臂连接,构建成一个特殊的人基因组λ噬菌体文库（富集文库）,效价为２×１０４．同时采用ＰＣＲ方法及用引物Ⅰ：５′ＧＧＡＣＡＧＧＣＴＡＣＡＴＣＡＧＧＡＡＧＡＧＧ３′,引物Ⅱ：５′ＣＴＧＣＧＴＣＴＡＡＴＴＧＣＡＧＴＡＧＴＴＣ３′,从人基因组ＤＮＡ中扩增出一段含胰岛素基因的１．３６ｋｂＤＮＡ片段,做为放射性标记探针,对文库进行了噬菌斑原位杂交筛选,从１×１０４个噬菌斑中筛选到一个含人胰岛素基因组基因的阳性克隆,并进一步完成了亚克隆和该基因１７３２ｂｐＤＮＡ序列的测定．结果该基因的１７３２ｂｐＤＮＡ序列包括部分５′端和３′端与国外发表的人胰岛素α型等位基因的序列相同     

胰岛素B链N端的修饰及其生物活性变化

通过对在大肠杆菌体系中表达及部分加工的粗产物的反相快速蛋白液相色谱的分离,我们得到了Ｌ－Ｍｅｔ＾ＢＯ－人胰岛素原、Ｌ－Ｍｅｔ＾Ｂ－１－Ｌｙｓ＾ＢＯ－人胰岛素原,氨基酸组成分析结果与设想的完全一致,两者的胰岛素受体活性分别为人胰岛素原的６６％及５４％,而胰岛素的放射免疫活性分别降为人胰岛素原的２２％及９％。表明胰岛Ｂ链的Ｎ端对胰岛素分子与其受体的结合有一定的重要性,而更重要的是它非常可能参与组成胰岛     

高活力胰岛素研究：B3—Lys猪胰岛素的结晶及初步晶体学分析

用化学半合成方法制备的Ｂ３—Ｌｙｓ猪胰岛素（Ｂ３ＫＰＩ）具有与天然猪胰岛素相同的体内生物活力,但其体外生物活力及受体结合活力比天然猪胰岛素高。本文报道Ｂ３ＫＰＩ的晶体生长,初步晶体学分析及衍射数据与处理。Ｂ３ＫＰＩ晶体的衍射分辨率可以达到２．１Ａ（１Ａ＝０．１ｎｍ）,空间群为Ｒ３,晶胞参数为：ａＨ＝ｂＨ＝８２．２３ＡＣＨ＝３４．１７Ａ．收集了一套２．１Ａ分辨率的衍射数据,数据完全度为８１％,Ｒｍｅｒｇｅ为２．９％。     

胰岛素蛋白质工程：高活性［B10Asp］人胰岛素

用基因定位突变方法将胰岛素Ｂ链第１０位的Ｈｉｓ变为Ａｓｐ,获得高活力胰岛素──［Ｂ１０Ａｓｐ］人胰岛素。其受体结合能力和离体生物活力分别为猪胰岛素的２６２％和２３５％;体内生物活力也明显高于猪胰岛素;它的促细胞生长能力为猪胰岛素的１７４％。     

一种重组抗胰蛋白酶单体人胰岛素突变体的设计、制备和鉴定

用缺口双链DNA的定向突变方法分别将胰岛素前体中B链第 2 2、2 8、2 9和 3 0位改变为Asp、Lys、Pro和Lys,酵母分泌表达的前体经胰蛋白酶直接酶切 ,得到重组 [B2 2Asp、B2 8Lys、B2 9Pro、B3 0Lys]人胰岛素。它与受体的结合能力约为猪胰岛素的 6% ,而体内生物活力保留 5 0 %。通过FPLC分子筛测定其自身结合能力 ,在生理条件下浓度达 10 -4mol/L时它以单体形式存在。作为可抗胰蛋白酶酶解的单体胰岛素类似物 ,它可能具有一定的应用前景     

Changes in secondary structure follow the dissociation of human insulin hexamers: a circular dichroism study

Vacuum UV circular dichroism spectra measured down to 178 nm for hexameric 2-zinc human insulin, zinc-free human insulin, and the two engineered and biologically active monomeric mutants, [B/S9D] and [B/S9D,T27E] human insulin, show significant differences. The secondary structure analysis of the 2-zinc human insulin (T6) in neutral solution was determined: 57% helix, 1% beta-strand, 18% turn, and 24% random coil. This is very close to the corresponding crystal structure showing that the solution and solid structures are similar. The secondary structure of the monomer shows a 10-15% increase in antiparallel beta-structure and a corresponding reduction in random coil structure. These structural changes are consistent with an independent analysis of the corresponding difference spectra. The advantage of secondary structure analyses of difference spectra is that the contribution of odd spectral features stemming mainly from side chain chromophores is minimized and the sensitivity of the analyses improved. Analysis of the CD spectra of T6 2-zinc, zinc-free human insulin and monomeric mutant insulin by singular value decomposition indicates that the secondary structure changes following the dissociation of hexamers into dimers and monomers are two-state processes.     

Insulin stimulates GDP release from G proteins in the rat and human liver plasma membranes

Plasma membranes (1–2 mg protein) prepared from the livers of adult male rats and human organ donors were incubated with 0.6 μM [α-³²P] guanosine triphosphate (GTP) in an adenosine triphosphate (ATP)-regenerating buffer at 37°C for 1 h; during this incubation, the [³²P]GTP is hydrolyzed and the nucleotide that is predominantly bound to the membranes is [³²P] guanosine diphosphate (GDP). [³²P]GDP release from the liver membranes was proportional to the protein concentration and increased as a function of time. At 5 mM, Ca²⁺, Mg²⁺, Mn²⁺, and Zn²⁺ maximally inhibited GDP release by 80–90%, whereas, 5 mM Cu²⁺ maximally stimulated the reaction by 100%. Therefore, cations were not included in the buffer used in the GDP release step. One μM Gpp(NH)p (5′-guanylylimidodiphosphate), a nonhydrolyzable analog of GTP, maximally stimulated [³²P]GDP release in the liver membranes by up to 30%. Although 10 nM Gpp(NH)p had no effect on GDP release, it appeared to stabilize the hormonal effect by blocking further GDP/GTP exchange. In the rat membranes, 1–100 nM glucagon (used as a positive control) stimulated [³²P]GDP release by about 17% (P < .05); similarly, 0.1–100 nM insulin stimulated [³²P]GDP release by 10–13% (P < .05). In the human membranes, 10 pM to 100 nM insulin stimulated [³²P]GDP release by 7–10%. In the rat membranes, 10 nM insulin stimulated [³²P]GDP release by 17 and 24% at 2 and 4 min, respectively (P < .05); in the human membranes, 10 nM insulin stimulated [³²P]GDP release by about 9% at 2 and 4 min. Normal rabbit IgG (used as a control for insulin receptor antibody) by itself stimulated the GDP release by rat and human membranes. However, the stimulation of the GDP release by insulin receptor antibody was consistently higher than that observed with normal rabbit IgG. Four to 15 μg of insulin receptor antibody stimulated [³²P]GDP release by 12–22% (P < .05) and 7–14% in rat and human membranes, respectively. These results indicate that ligand binding to the insulin receptor results in a functional interaction of the receptor with a guanine nucleotide-binding transducer protein (G protein) and activation of GTP/GDP exchange.     

TyrB26位点改变的人类胰岛素类似物的化学合成与体外活性

摘要：为了研究人类胰岛素B链第26位的酪氨酸对胰岛素和受体之间的结合的影响,包括单独的氨基酸替换或化合物替换的不同的胰岛素类似物被合成,其中化合物替代的类似物的B链C末端都减少了4个氨基酸。在对它们与胰岛素受体的亲和力进行研究中,结果发现它们与胰岛素受体的亲和力没有丢失, HisB26类似物和N-MeHisB26类似物的结合能力与胰岛素相比改变不大,分别是胰岛素的72 %和107 %。N-MeGluB26类似物,AadB26类似物和Phe (4-carboxy) B26类似物的结合能力有很大的提高,分别是130 %, 234 %和160 %。     

[B2-Lys]-胰岛素的制备与性质

本文报道了用化学半合成途径从天然猪胰岛素制备[B2-Lys]-胰岛素的过程。人胎盘细胞膜胰岛素受体结合试验表明:[B2-Lys]-胰岛素的受体结合能力只有天然胰岛素的80％,降兔血糖作用与时间关系的结果表明它没有长效作用。本文还对这些结果进行了讨论。     

Protein engineering of insulin: Two novel fast-acting insulins [B16Ala]insulin and [B26Ala]insulin

Blood glucose lowering assay proved that [B16Ala]insulin and [B26Ala]insulin exhibit potency of acute blood glucose lowering in normal pigs, which demonstrates that they are fast- acting insulin. Single-chain precursor of [B16Ala]insulin and [B26Ala]insulin is [B16Ala]PIP and [B26Ala]PIP, respectively, which are suitable for gene expression. Secretory expression level of the precursors in methylotrophic yeast Pichia pastoris was quite high, 650 mg/L and 130 mg/L, respectively. In vivo biological assay showed that the two fast-acting insulins have full or nearly full biological activity. So both [B16Ala]insulin and [B26Ala]insulin can be well developed as fast-acting insulin for clinic use.     

Toward understanding the role of insulin alpha-helix II in the growth-promoting activity of insulin.

For further understanding the contribution of the alpha-helix II (alphaII) in the growth-promoting activity of insulin, the residues A2Ile, A5Gln, and A8Thr located in alphaII were mutated to Leu, Glu, and Tyr, respectively. Three mutant insulins, [A2Leu]human insulin, [A5Glu]human insulin, and [A8Tyr]human insulin, were prepared by means of site-directed mutagenesis. The in vitro growth-promoting activities of the three mutant insulins, measured using GR2H6 cells, were 7.5%, 291%, and 250% of that of native insulin, respectively. Their receptor-binding activities to the insulin receptor were 2.3%, 46.7%, and 138.7%, respectively, compared with native insulin. Both the growth-promoting and receptor-binding activities of [A2Leu]human insulin and [A3Leu]insulin (Shi et al., 1997) were parallel and greatly decreased compared with native insulin. The results demonstrate that the residues A2Ile and A3Val in the alphaII are essential for the growth-promoting activity of insulin, and the growth-promoting function of insulin might be performed through, or mainly through, binding to the insulin receptor. The growth-promoting activities of [A5Glu]human insulin and [A8Tyr]human insulin were increased 6-fold and 2-fold, respectively, compared with native insulin, indicating that their growth-promoting activities might be expressed by, or mainly by, binding to the IGF-1 receptor.     

B22 Glu Des-B30 Insulin： A Novel Monomeric Insulin

Studies on monomeric insulin with reduced self-association are important in the development of insulin pharmaceutical preparations with rapid hypoglycemic action on patients with diabetes. Here we report a novel monomeric insulin, B22 Glu des-B30 insulin, prepared from a single chain insulin precursor with B22 Arg mutated to Glu, which was expressed in Pichia pastoris and converted to B22 Glu des-B30 insulin by tryptic digestion. It still retains 50% of the in vivo biological activity of porcine insulin and does not form a dimer even at a concentration of 10 mg/ml, showing that B22 Glu plays a key role in reducing the self- association of the insulin molecule without greatly reducing its biological activity. This novel monomeric insulin might have potential applications in the clinic.     

Protein engineering of insulin: Two novel fast-acting insulins [B16Ala]insulin and [B26Ala]insulin

Insulin has been successfully used in clinic treatment of diabetes for more than 80 years. However, the clinic practice has shown that regular insulin preparation used in clinic exhibits several intrinsic problems that have existed for a long time. One of the major problems is that insulin has a potency of self-association when its concentration is higher than physiological concentration (10-8—10-10 mol/L)[1,2]. The concentration of the regular insulin is higher than 10-4 mol/L. At such a hi…